WPD Pharmaceuticals (WBIO) AI Stock Analysis

• Market Cap: C$324.76K
• Dividend Yield: N/A
• Average Volume (3M): 0.00
• Price to Earnings (P/E): ―
• Beta (1Y): -0.16
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: CA
• Employees: 16
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 4,639,485
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 0
• PEG Ratio: 15.70
• Price to Book (P/B): -230.88
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -625.84
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 22 Underperform
• Price Target: ―
• Action: N/A Date: 01/14/25
• Date: Action: N/A 01/14/25

WPD Pharmaceuticals' stock score is significantly impacted by its poor financial performance, characterized by zero revenue, high debt, and negative cash flows. Technical analysis indicates a bearish trend, while valuation metrics are unfavorable due to a negative P/E ratio and lack of dividend. The overall outlook for the stock is negative, with significant financial instability and market weakness.

WPD Pharmaceuticals Business Overview & Revenue Model

Company Description

WPD Pharmaceuticals Inc. engages in the research and development of medicinal products in the fields of oncology and infectious diseases. Its drug development pipeline includes WPD101 to treat brain cancers, including glioblastoma that is in the pre-clinical trial; WPD102 to treat Uval Melanoma, which is in the pre-clinical trial; Berubicin for the treatment of glioblastoma that us in phase 1 clinical trial; and WP1066 to treat central nervous system tumors, pancreatic cancer, and ocular tumors, which is in phase 1 clinical trial. The company's drug development pipeline also includes WP1732 for the treatment of pancreatic cancer; WP1220 to treat cutaneous T-cell lymphoma; WPD103 for the treatment of glioblastoma multiforme that is in the pre-clinical trial; and Annamycin to treat acute myeloid leukemia (AML) and metastasis to lungs, which is in Phase I/II clinical trials in AML. WPD Pharmaceuticals Inc. is headquartered in Vancouver, Canada.

How the Company Makes Money

WPD Pharmaceuticals makes money through the development and commercialization of its drug candidates. Revenue is primarily generated from licensing agreements, milestone payments, and royalties from strategic partnerships with larger pharmaceutical companies. These collaborations often involve co-development and co-marketing arrangements, which provide essential funding and resources for clinical trials and regulatory approvals. Additionally, WPD may receive grants or subsidies from governmental or non-governmental organizations to support its research activities.

WPD Pharmaceuticals Financial Statement Overview

Summary

WPD Pharmaceuticals faces significant financial challenges with zero revenue, high debt, and negative cash flows. The company's financial position is precarious, and it needs to address these issues to improve stability and growth prospects.

Income Statement

The company has reported zero revenue consistently, indicating a lack of sales or operational activity, which is reflected in negative EBIT and net income. The absence of revenue growth and low profitability margins are significant weaknesses.

Balance Sheet

The company has a negative stockholders' equity, indicating insolvency. The high debt level compared to equity is a risk factor. The equity ratio is also negative, reflecting financial instability.

Cash Flow

Negative free cash flow and operating cash flow highlight cash management issues. The company relies heavily on financing activities to fund operations, which may not be sustainable in the long term.

Breakdown	TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	-24.44K	-290.22K	-391.77K	―
EBITDA	63.10K	-40.43K	4.05M	-5.24M	-7.11M	-11.45M
Net Income	-6.71K	-80.08K	3.86M	-5.62M	-7.52M	-12.78M
Balance Sheet
Total Assets	292.54K	346.41K	75.85K	1.86M	2.68M	4.07M
Cash, Cash Equivalents and Short-Term Investments	9.34K	85.86K	23.79K	1.71M	1.24M	2.95M
Total Debt	390.88K	303.90K	0.00	1.04M	115.38K	254.51K
Total Liabilities	914.82K	902.37K	554.64K	5.92M	1.58M	864.48K
Stockholders Equity	-622.29K	-555.96K	-478.79K	-4.06M	1.11M	3.21M
Cash Flow
Free Cash Flow	-171.99K	-205.10K	-3.47M	-1.56M	-2.03M	-235.52K
Operating Cash Flow	-171.99K	-205.10K	-3.43M	-1.49M	-1.38M	-170.40K
Investing Cash Flow	7.37K	0.00	-239.05K	-70.98K	-645.46K	2.81M
Financing Cash Flow	30.50K	267.17K	1.23M	992.22K	1.02M	380.92K

WPD Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ENBI	47 Neutral	C$1.39M	-6.62	-107.76%	―	―	34.22%
WBIO	22 Underperform	C$324.76K	-38.89	1.08%	―	―	―